Chapters
Transcript
Data shows antibody-drug conjugate offers significant survival benefit for patients with HR-positive/HER2-negative metastatic breast cancer.
Related Presenters
Sara Tolaney, MD, MPH
Medical Oncology
View full profile
Related Videos
ASCO 2023: Bladder Cancer Highlights Presented By Charlene Mantia, MD
ASCO 2023: Prostate Cancer Highlights Presented By Jacob Berchuck, MD
ASCO 2023: Kidney Cancer Highlights Presented By Vincent (Wenxin) Chu, MD
ASCO 2023: Breast Cancer Research Presented by Jennifer Ligibel, MD
ASCO 2023: Prostate Cancer Research Presented by Praful Ravi, MB BCHIR, MRCP
ASCO 2023: Treating NUT Carcinoma Research Presented by Jia Luo, MD
ASCO 2023: Kidney Cancer Research Presented by Toni Choueiri, MD
ASCO 2023: Breast Cancer Research Presented by Paolo Tarantino, MD
ASCO 2023: Head And Neck Research Presented by Glenn Hanna, MD
Marla Lipsyc-Sharf, MD on ctDNA in Breast Cancer
Impact of Angiotensin Blockade on Response to PD1/L1 Inhibitors for Patients with Metastatic Urothelial Carcinoma (mUC)
Post-Radical Prostatectomy (RP) Outcome for Patients with High-Risk Prostate Cancer Treated with Intense Neoadjuvant Hormone Therapy (NHT): Results of a Pooled Analysis of Contemporary Clinical Trials
Cancer
Cardiology
Gastroenterology
Neurology
OBGYN
Orthopedics
Pediatrics
BroadcastMed News
Dermatology
Diabetes & Endocrinology
Infectious Diseases
Ophthalmology
Optometry
Otolaryngology
Pulmonology
Surgery
Urology
About
Solutions
Resources
Contact
person Sign In / Create Account
